Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

: NHANES LBXGLU Variable Definition - TTL Representation

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix loinc: <https://loinc.org/rdf/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:Group ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "282882"] ; # 
  fhir:meta [
fhir:versionId [ fhir:v "5" ] ;
fhir:lastUpdated [ fhir:v "2025-03-26T21:52:45.205Z"^^xsd:dateTime ]
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "empty" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"^^rdf:XMLLiteral
  ] ; # 
  fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-author"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
fhir:name [ fhir:v "Brian S. Alper" ]     ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as"^^xsd:anyURI ] ;
fhir:value [
a fhir:markdown ;
fhir:v "NHANES LBXGLU Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-15. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882#json."     ]
  ] ) ; # 
  fhir:url [ fhir:v "https://fevir.net/resources/Group/282882"^^xsd:anyURI] ; # 
  fhir:identifier ( [
fhir:type [
      ( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ]       ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ]     ] ;
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "https://fevir.net/FOI/282882" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ]     ]
  ] ) ; # 
  fhir:title [ fhir:v "NHANES LBXGLU Variable Definition"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:publisher [ fhir:v "Computable Publishing LLC"] ; # 
  fhir:contact ( [
    ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."] ; # 
  fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; # 
  fhir:membership [ fhir:v "conceptual"] ; # 
  fhir:combinationMethod [ fhir:v "all-of"] ; # 
  fhir:characteristic ( [
fhir:code [
fhir:text [ fhir:v "Laboratory test" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
      ( fhir:coding [
a loinc:1558-6 ;
fhir:system [ fhir:v "http://loinc.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "1558-6" ] ;
fhir:display [ fhir:v "Fasting glucose [Mass/volume] in Serum or Plasma" ]       ] ) ;
fhir:text [ fhir:v "Fasting plasma glucose" ]     ] ;
fhir:exclude [ fhir:v false ]
  ] [
fhir:code [
fhir:text [ fhir:v "Unit of measure" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "mg/dL" ]     ] ;
fhir:exclude [ fhir:v false ]
  ] [
fhir:code [
fhir:text [ fhir:v "Method" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis.   Plasma Fasting Glucose Laboratory Procedure Manual (August 2020)   https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf" ]     ] ;
fhir:exclude [ fhir:v false ]
  ] ) . #